<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114251</article-id><article-id pub-id-type="publisher-id">ACM-41757</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_85633696.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  结直肠癌的诊断与治疗新进展
  New Progress in Diagnosis and Treatment of Colorectal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>海军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>铁成</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>涛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>曹</surname><given-names>波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>恺鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院胃肠疝外科，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1117</fpage><lpage>1124</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    结直肠癌(the colorectal cancer, CRC)是消化道常见的恶性肿瘤。近年来发病率依然较高，仍存在许多早期、中期患者被忽视或延误病情的情况。因此，对于CRC的二、三级预防尤为重要。包括对高危患者行粪便隐血试验OB、电子结肠镜、直肠指诊有利于疾病的早期发现，此外对于确诊为CRC的，应力争提高生存质量，延长寿命，降低病死率。目前，对于CRC的治疗方法包括内镜下切除，根治性手术切除，术前全身放化疗降低肿瘤分期的手术切除，转移灶的局部切除治疗以及姑息切除，全身放化疗、靶向和免疫治疗等。本文结合近年来国内外对CRC的诊断、治疗及预后方面的新研究进展展开综述。
    Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. In recent years, the incidence rate is still high, and there are still many early and mid-stage patients who are neglected or delayed in their illness. Therefore, the secondary and tertiary prevention of CRC are particularly important. Including high-risk patients with stool occult blood test OB, electronic colonoscopy, and digital rectal examination are conducive to the early detection of the disease. In addition, for those diagnosed with CRC, we should strive to improve the quality of life, prolong life, and reduce the mortality rate. At present, the treatment methods for CRC include endoscopic resection, radical surgical resection, preoperative systemic radiotherapy and chemotherapy to reduce tumor stage surgical resection, local resection and palliative resection of metastases, systemic radiotherapy and chemotherapy, targeted therapy and immunotherapy Wait. This article summarizes the new research progress in the diagnosis, treatment and prognosis of CRC at home and abroad in recent years. 
  
 
</p></abstract><kwd-group><kwd>结直肠癌，结直肠肿恶性瘤，CRC，结直肠癌的诊断与治疗, Colorectal Cancer</kwd><kwd> Malignant Tumor of Colorectal Tumor</kwd><kwd> CRC</kwd><kwd> Diagnosis and Treatment of 
Colorectal Cancer</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>结直肠癌(the colorectal cancer, CRC)是消化道常见的恶性肿瘤。近年来发病率依然较高，仍存在许多早期、中期患者被忽视或延误病情的情况。因此，对于CRC的二、三级预防尤为重要。包括对高危患者行粪便隐血试验OB、电子结肠镜、直肠指诊有利于疾病的早期发现，此外对于确诊为CRC的，应力争提高生存质量，延长寿命，降低病死率。目前，对于CRC的治疗方法包括内镜下切除，根治性手术切除，术前全身放化疗降低肿瘤分期的手术切除，转移灶的局部切除治疗以及姑息切除，全身放化疗、靶向和免疫治疗等。本文结合近年来国内外对CRC的诊断、治疗及预后方面的新研究进展展开综述。</p></sec><sec id="s2"><title>关键词</title><p>结直肠癌，结直肠肿恶性瘤，CRC，结直肠癌的诊断与治疗</p></sec><sec id="s3"><title>New Progress in Diagnosis and Treatment of Colorectal Cancer<sup> </sup></title><p>Haijun Zhou, Tiecheng Bai, Tao Liu, Bo Cao, Kaipeng Li</p><p>Department of Gastrointestinal Hernia, Affiliated Hospital of Yan’an University, Yan’an Shaanxi</p><p><img src="//html.hanspub.org/file/44-1572164x4_hanspub.png" /></p><p>Received: Mar. 19<sup>th</sup>, 2021; accepted: Apr. 15<sup>th</sup>, 2021; published: Apr. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/44-1572164x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Colorectal cancer (CRC) is a common malignant tumor of the digestive tract. In recent years, the incidence rate is still high, and there are still many early and mid-stage patients who are neglected or delayed in their illness. Therefore, the secondary and tertiary prevention of CRC are particularly important. Including high-risk patients with stool occult blood test OB, electronic colonoscopy, and digital rectal examination are conducive to the early detection of the disease. In addition, for those diagnosed with CRC, we should strive to improve the quality of life, prolong life, and reduce the mortality rate. At present, the treatment methods for CRC include endoscopic resection, radical surgical resection, preoperative systemic radiotherapy and chemotherapy to reduce tumor stage surgical resection, local resection and palliative resection of metastases, systemic radiotherapy and chemotherapy, targeted therapy and immunotherapy Wait. This article summarizes the new research progress in the diagnosis, treatment and prognosis of CRC at home and abroad in recent years.</p><p>Keywords:Colorectal Cancer, Malignant Tumor of Colorectal Tumor, CRC, Diagnosis and Treatment of Colorectal Cancer</p><disp-formula id="hanspub.41757-formula39"><graphic xlink:href="//html.hanspub.org/file/44-1572164x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/44-1572164x7_hanspub.png" /> <img src="//html.hanspub.org/file/44-1572164x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>CRC (the colorectal cancer, CRC)是消化道最常见的肿瘤，严重影响着人们的生命健康。随着人们健康意识、诊疗水平的提高，疾病诊出率显著提高 [<xref ref-type="bibr" rid="hanspub.41757-ref1">1</xref>]。对于包括CRC在内的所有疾病，重在三级预防，由于CRC的病因尚不明确，早发现、早诊断、早治疗对其有重要意义。提高人们对疾病的认识、增强临床医生对此类有高危因素的病患早期筛查、诊断理念，能提高疾病诊出率 [<xref ref-type="bibr" rid="hanspub.41757-ref2">2</xref>]；此外，对诊断为肿瘤的患者早期发现与有效的治疗能遏制其发展，改善晚期治疗策略和预后，提高其生存率 。2018版美国肿瘤联合会(AJCC)分期系统的提出和应用，对CRC临床、病理pTNM分期的更细化，CRC的诊断和治疗进入新时期。</p></sec><sec id="s6"><title>2. 病因及病理分型</title><p>目前，认为肿瘤的发生发展是多步骤、多阶段及多基因参与的细胞遗传性疾病。在肿瘤发展过程中，包括原癌基因的激活、抑癌基因的抑制、错配修复基因的突变及基因的过渡表达共同参与癌症的促成。有研究认为，肠道菌群失调可能增加罹患CRC的风险 [<xref ref-type="bibr" rid="hanspub.41757-ref3">3</xref>]。</p><p>CRC的病理大体分型包括隆起型、溃疡型及浸润型(结肠癌常见)。</p><p>2018 AJCC分期系统对区域淋巴结N及远处转移M做出了新的定义及分期。肿瘤沉积(tumor deposits，TD)：指沉积于肠系膜脂肪组织内的肿瘤结节，无可辨认的淋巴、血管、神经结构。M1分为M1a (一个器官或部位侵犯)和M1b (&gt;1个器官或部位受侵犯，无腹膜侵犯)。M1c：只要存在腹膜转移，无论是否有其他器官的侵犯，此类预后差。</p></sec><sec id="s7"><title>3. 临床表现</title><p>1) 结肠癌：a) 排便性状和习惯的改变通常为首要表现，如便秘、腹泻、大便次数增多、粘液脓血便等。b) 腹痛和腹部：常表现为腹部不适感，间断性隐痛、胀痛，定位不准确，急性梗阻时可出现急性肠梗阻的表现；c) 此外，部分病人可于腹部病变部位触及腹部包块，多质地坚硬，活动度可因为肿瘤部位不同而不同，如乙状结肠、横结肠肿块活动度较大。中晚期结肠癌病人多以不完全或完全性肠梗阻为首发症状，多表现为腹胀、腹痛，便秘等，完全梗阻时可加重伴有明显恶心、呕吐、排气、排便停止等急性肠梗阻表现。全身表现：右半结肠癌病人多以贫血、消瘦、乏力等全身中毒症状为表现；左半结肠病人多以肠梗阻、便血、便秘及腹泻为主。晚期可因全身器官侵犯表现为主，如肝脏、腹膜侵犯时可有肝大、黄疸、腹水、左锁骨上淋巴结大及恶病质表现。</p><p>2) 直肠癌：便频、便血、脓血变等排便习惯和性状改变，肛门下坠感、里急后重感或腹痛为主的直肠刺激症状；因梗阻所致的大便变细或肠梗阻表现。晚期侵犯周围器官造成相应症状：如膀胱侵犯造成尿频、尿急、尿痛、血尿等膀胱刺激症状；骶神经侵犯造成持续性疼痛；肝脏、腹膜、肺脏及骨骼受累。</p></sec><sec id="s8"><title>4. 诊断</title><p>1) 结肠癌：凡是40岁以上具有结肠癌高危因素的人群均常规应行纤维结肠镜或X线钡剂灌肠。以下人群应视为存在高危因素：a) 有CRC的家族史；b) 存在其他肿瘤史，有胃肠道的腺瘤、息肉病史；c) 粪便隐血实验OB(+)。d) 有粘液脓血便(除外溃疡性结肠炎、痢疾等疾病时)史，便秘腹泻交替史。</p><p>2) 直肠癌：直肠指诊：对于高危人群(排便性状、习惯改变、便血等)常规进行。</p><p>3) 内镜检查：包括肛门镜、乙状结肠镜及纤维结肠镜在内的内镜检查，观察病灶并行病理学检查，更进一步明确诊断。超声内镜检查(EUS)：对于低位直肠癌推荐行该项目，监测及评估肿瘤侵犯深度及有无周围脏器侵犯 [<xref ref-type="bibr" rid="hanspub.41757-ref4">4</xref>]。屠世良等 [<xref ref-type="bibr" rid="hanspub.41757-ref5">5</xref>] 认为CRC的浸润深度是淋巴结转移发生的最主要因素，且术前血清癌胚抗原CEA水平的上升提示淋巴结转移的发生。</p><p>4) CT检查：可明确有肿瘤的病灶本身，有无引流区域淋巴结肿大、周围脏器侵犯及肝脏转移。八版AJCC指南删除了盆腔CT检查，将EUS和MRI用于直肠癌的浸润深度及范围评估，从而指导是否需行新辅助化疗。有研究指出CT仿真结肠镜联合肿瘤标志物检测能够提高CRC的临床诊断效能 [<xref ref-type="bibr" rid="hanspub.41757-ref6">6</xref>]。</p><p>5) PET-CT检查：PET-CT融合成像能对病灶准确定位定性，除外有无远处器官的转移。用于原发灶诊断、术前评估和分期 [<xref ref-type="bibr" rid="hanspub.41757-ref7">7</xref>]，此外用于术后复发、转移的监测也具有很高的灵敏性 [<xref ref-type="bibr" rid="hanspub.41757-ref8">8</xref>]。</p><p>6) 腹部超声检查：对于CRC存在10~15%肝转移的可能性，因此应常规行超声或CT。</p><p>7) 肿瘤标记物：大量研究表明CRC病人血清CEA水平与分期呈正相关，且随分期级别升高，其阳性率升高。CA199在胃肠道肿瘤及胰腺癌中均可见明显增高 [<xref ref-type="bibr" rid="hanspub.41757-ref9">9</xref>]，在临床多用于胰腺癌的诊断 [<xref ref-type="bibr" rid="hanspub.41757-ref10">10</xref>]。二者均可用于CRC的预后及复发的监测。肿瘤相关糖蛋白抗原CA72-4在胃肠道癌、卵巢癌、乳癌中均有增高 [<xref ref-type="bibr" rid="hanspub.41757-ref11">11</xref>]。三者常同时用于CRC的诊断和预后监测。一项研究CRC远处转移影响因素的分析，经多因素Cox比例风险回归模型显示年龄、CEA、CA19-9是远处转移的高危因素 [<xref ref-type="bibr" rid="hanspub.41757-ref12">12</xref>]。血清甲胎蛋白AFP可用于结直肠癌肝脏转移(CRLM)的协助诊断。</p><p>8) 其他：淋巴结活检对于怀疑低位直肠癌并腹股沟淋巴结大时，应行该检查；若合并妇科或泌尿系侵犯，行相应检查进一步明确。</p></sec><sec id="s9"><title>5. 治疗</title><p>CRC的治疗应建立在明确的TNM分期基础之上。CRC治疗包括：手术治疗、放疗、化疗、免疫治疗，以手术切除为主的综合治疗是治疗CRC的主要手段 [<xref ref-type="bibr" rid="hanspub.41757-ref13">13</xref>]。</p><sec id="s9_1"><title>5.1. 手术治疗</title><p>1) cT0N0M0期CRC：内镜治疗或局部切除。</p><p>适应症为：仅适用于T1期高–中分化肿瘤；最大径 &lt; 3 cm、侵犯肠周 &lt; 30%、切缘距离肿瘤 &gt; 3 mm、肿瘤活动，不固定。术后pT1期，观察随访；pT2期，具有预后不良的组织学特征，或者非完整切除，标本破碎切缘无法评价)，后续推荐追加结肠切除术加区域淋巴结清扫。</p><p>2) T2-4N0-2M0 期CRC</p><p>结肠癌：最新指南推荐行 [<xref ref-type="bibr" rid="hanspub.41757-ref14">14</xref>] CME + D3根治联合手术，即相应结肠肠段的切除 + 区域淋巴结清扫(D3根治术)，要求在膜解剖层面保证系膜的完整切除，并且完成D3水平的血管高位结扎和系膜根部淋巴结的清扫。</p><p>直肠癌：推荐行直肠癌根治术：切除原发肿瘤，保证足够切缘，切除直肠系膜内淋巴脂肪组织及可疑阳性的侧方淋巴结。保证直肠系膜完整切除即切除足够长度的肠管并遵循直肠全系膜切除术TME原则。手术切缘：近切缘肿瘤至少5 cm，远切缘距肿瘤至少2 cm。有报道指出：直肠癌远端切缘1 cm处癌灶的残留概率为4%~10%，远端切除2 cm处癌灶的残留概率为0~2% [<xref ref-type="bibr" rid="hanspub.41757-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41757-ref16">16</xref>]，而远端切缘 [<xref ref-type="bibr" rid="hanspub.41757-ref17">17</xref>] 阳性可导致较高的局部复发 [<xref ref-type="bibr" rid="hanspub.41757-ref17">17</xref>]。若下段直肠癌因保肛导致远切缘距肿瘤1~2 cm时，建议行术中快速冰冻病理学检查证实切缘阴性。中下段直肠肿瘤应遵循(TME)原则。对于侧方淋巴结清扫推荐切除可疑阳性的侧方淋巴结。</p><p>3) 对于可切除，伴有急性肠梗阻病例，采用一期病损切除 + 淋巴结清扫，或支架植入解除梗阻后期再行手术。封益飞等 [<xref ref-type="bibr" rid="hanspub.41757-ref18">18</xref>] 对比了肠道支架置入联合择期手术和急诊手术治疗梗阻性CRC后认为：前者更安全、可靠，并且在提高I期吻合率、降低造口率、促进术后恢复方面具有显著优势。对于不可切除伴梗阻者行结肠造口或内镜下支架植入术，根据需要姑息性切除，放化疗。</p></sec><sec id="s9_2"><title>5.2. 辅助治疗</title><p>根据术后病理pTNM分期进行指导后续治疗。有研究指出：术前新辅助治疗可以杀灭影像学阴性的小转移灶，减小根治术后远处转移的发生率 [<xref ref-type="bibr" rid="hanspub.41757-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.41757-ref20">20</xref>]。T3N0M0前无高危因素者可不行辅助治疗，术后定期随访、复查；T3N0M0复发风险高的，T1~4N1~2M0，给予5FU/LV或希罗达、或FOLFOX方案，后期定期随访、复查CEA，CT及肠镜。II期CRC是否行新辅助化疗及如何选择成为焦点 [<xref ref-type="bibr" rid="hanspub.41757-ref21">21</xref>]。肖刘牛的一项Meta分析表明：II期CRC术后常规化疗，对于总生存率、复发率无明显提高。在相关危险因素的分析中发现：存在T4期、低分化或未分化、伴肠梗阻或肠穿孔、伴淋巴/血管或周围神经浸润、伴不充足淋巴结检出数的等高危因素患者，术后化疗均可显著提高临床疗效 [<xref ref-type="bibr" rid="hanspub.41757-ref22">22</xref>]。T3期及任何T分期，淋巴结阳性且无放化疗禁忌症的直肠癌可行联合放化疗，将其降期后手术治疗。放疗剂量总量45~54 Gy，采用常规分割剂量(通常为35 d)，希罗达/5-FU为主 + 放疗(5周)，放化疗后6~8周后性指直肠癌根治术。伴有肝转移：放疗 + 奥沙利铂、5-FU、靶向药物 + 卡培他滨。对于局部进展期直肠癌出现了全程新辅助治疗(TNT)，即将术后辅助化疗提前至术前，给予新辅助化疗和同步放化疗，可获得更高的完全缓解率，有助于器官保留，还可减少远处转移，改善长期生存 [<xref ref-type="bibr" rid="hanspub.41757-ref21">21</xref>]。</p><p>1) III期及以上CRC的治疗</p><p>III期CRC应行辅助化疗。III期结肠癌，术后辅助化疗能提高5年无病生存率及总生存率，可给予FOLFOX &#177; 靶向药物、CapeOX &#177; 靶向药物、FOLFIRI &#177; 靶向药物、5-FU/LV或卡培他滨单药化疗 [<xref ref-type="bibr" rid="hanspub.41757-ref23">23</xref>]。对于高危(T4、组织分化差、肿瘤周围淋巴管神经侵犯、肠梗阻、T3伴有局部穿孔、切缘不确定或阳性、淋巴结活检数量少于12个)的II期患者，应予以辅助化疗，方案同上 [<xref ref-type="bibr" rid="hanspub.41757-ref24">24</xref>]。</p><p>对于术前未行放化疗的T3及以上或任何T分期但淋巴结阳性的中低位直肠癌患者，术后辅助化疗或放化疗能提高3年无病生存率及降低局部复发率 [<xref ref-type="bibr" rid="hanspub.41757-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.41757-ref26">26</xref>]。</p><p>2) CRC远处转移的治疗</p><p>CRC多经局部、淋巴及血行转移的方式向远处转移，多为腹膜、病灶周围脏器、肝脏、肺脏骨骼系统等转移，经血常规、生化及肿瘤标记物检查，CT、MRI、PET-CT甚至腹腔镜、血管造影、穿刺活检等明确存在远处转移的病例，诊断为CRC的远处转移。对于存在远处转移孤立的、小病灶可争取R0切除，辅以放化疗治疗，必要时加用靶向药物治疗。但对于大多远处转移的CRC，仅能行姑息性切除或全身放化疗、免疫治疗。有研究显示：对于有远处转移灶不可切除的、无症状的IV期患者，行姑息性切除原发灶后生存率明显提高 [<xref ref-type="bibr" rid="hanspub.41757-ref27">27</xref>]。也有大样本研究结果显示：姑息性切除的晚期CRC患者比没有未行原发灶切除的预后好 [<xref ref-type="bibr" rid="hanspub.41757-ref28">28</xref>]。可能是因为切除病损后减少了体内癌细胞数量，减少了远处扩散的几率，防止相关并发症，从而进一步避提高患者生存率。但对此，仍然缺乏相关研究的证实。</p><p>a) CRC肝转移(CRLM)</p><p>手术完全切除肝转移灶仍是目前治愈结直肠癌肝转移的最佳方法。对于CRLM可切除者，应在原发肿瘤切除+淋巴结清扫基础上，同时或随后行肝脏病变切除，也可行原发肿瘤切除 + 新辅助化疗(FOLFIRI或FOLFOX)并分期肝切除；术后给予5FU/LV或希罗达、或FOLFOX方案或肝动脉灌注化疗 &#177; 5FU/LV或观察，术后定期监测。对于不可切除的CRLM者，伴肝脏肿瘤负荷小，给予清除病灶治疗。其主要包括射频、微波消融、放疗、无水乙醇瘤注射等。化疗一线方案：FOLFOX &#177; 靶向药物，mFOLFIRI &#177; 靶向药物，IFL + 靶向药物，5-FU/LV + 靶向药物；二线治疗推荐：伊立替康，FOLFOX或伊立替康 + 希罗达滨，FOLFOX或伊立替康。对不能耐受的，采用希罗达/5-FU/LV &#177; 靶向药物，或静滴5-FU &#177; LV &#177; 靶向药物，或持续静滴5-FU/LV。</p><p>b) CRC肺转移</p><p>对于孤立的可切除转移病灶，在原发肿瘤切除 + 淋巴结清扫的基础上，行肺部转移灶切除术，术后给与辅助放化疗并定期监测。对伴有多个肿块的可切除的转移患者予以切除，术后可给与FOLFOX &#177; 靶向药物/FOLFIRI &#177; 靶向药物辅助治疗；不可切除肺转移患者，同CRLM的治疗。</p><p>c) CRC腹腔/腹膜转移</p><p>目前此类患者主要有全身化疗、肿瘤细胞减灭术(CRS)联合全身放化疗、CRS联合腹腔热灌注化疗(HIPEC)等，腹膜转移评分体系PCI评分是最适用于腹膜转移癌评估的临床标准 [<xref ref-type="bibr" rid="hanspub.41757-ref29">29</xref>]，CRS + HIPEC被认为是有效的方法 [<xref ref-type="bibr" rid="hanspub.41757-ref30">30</xref>]，可以尽可能消灭原发和转移灶，提高患者的生存期，降低复发的可能 [<xref ref-type="bibr" rid="hanspub.41757-ref31">31</xref>]。有研究表明，该方案治疗CRC腹膜转移3年存活率为40%，5年存活率为20%，疗效较单纯化疗效果好 [<xref ref-type="bibr" rid="hanspub.41757-ref32">32</xref>]。对于大多CRC腹膜转移，治疗目的是姑息性切除；对于可R0切除的孤立性转移灶，可考虑手术治疗切除 [<xref ref-type="bibr" rid="hanspub.41757-ref33">33</xref>]。之后，对于能承受高强度化疗的病例，可行辅助化疗，方案同CRLM。</p><p>d) CRC骨转移</p><p>CRC骨转移虽相对少见，通常合并远处转移，但近年发病率有上升趋势。常见部位是脊椎、骨盆，其确诊主要依靠影像学检查。此类患者可能出现剧烈骨痛等骨转移表现，多预后不良。治疗：骨保护药治疗、全身放化疗、靶向或免疫治疗、手术及镇痛对症治疗。双膦酸盐能减少骨质破坏、吸收，从而减少病理性骨折、脊髓压迫、高钙血症等骨相关事件发生 [<xref ref-type="bibr" rid="hanspub.41757-ref34">34</xref>]。免疫治疗可以抑制破骨细胞的活性和减少骨破坏,从而缓解骨痛 [<xref ref-type="bibr" rid="hanspub.41757-ref35">35</xref>]。放射性核素治疗能杀伤、遏制癌细胞，从而控制、消除转移灶的目的 [<xref ref-type="bibr" rid="hanspub.41757-ref36">36</xref>]。靶向与化疗联合应用也可以提高此类患者的疗效并延长生存。</p></sec></sec><sec id="s10"><title>6. 预后</title><p>与CRC预后相关的包括：结直肠系膜的完整性，环周切缘(circumferential resection margins, CRM)、pTNM、临床cTNM、肿瘤退变分级(tumor regression grade)、RAS、BRAF基因改变以及微卫星不稳定性(microsatellite instability, MSI)及错配修复缺失检测(deficient mismatch repair, dMMR)。因此，对于CRC病人，术后生物学标记物及基因检测对于临床指导，意义重大。</p><p>RAS基因，不仅可以预测预后，也是预测表皮生长因子受体药物治疗有效性的标志 [<xref ref-type="bibr" rid="hanspub.41757-ref37">37</xref>]。</p><p>BRAF基因突变与CRC预后不良相关，并且指导其治疗方案的选择。一项纳入966例CRC的研究显示KRAS突变与年龄、性别、肿瘤分化程度及部位有关，BRAF基因突变型仅与肿瘤分化程度及部位有关 [<xref ref-type="bibr" rid="hanspub.41757-ref38">38</xref>]；BRAF基因突变率高，该突变型患者中位生存时间显著缩短，BRAF基因突率低，且该型CRC预后不良的独立危险因素 [<xref ref-type="bibr" rid="hanspub.41757-ref39">39</xref>]。MMR基因包括：MLH1、MSH2、PMS2、MSH6等，维持基因组完整 [<xref ref-type="bibr" rid="hanspub.41757-ref40">40</xref>]。MSI是指短串联重复序列(编码区和非编码区)普遍不稳定。CRC患者应行错配修复基因(MMR)/微卫星不稳定性(MSI)检测，指导后续治疗。一项基于1394例的研究显示：微卫星不稳定性dMMR在CRC的主要类型为MLH-1、PMS-2双缺失，病理特征表现典型 [<xref ref-type="bibr" rid="hanspub.41757-ref41">41</xref>]。MSI或DNA错配修复基因的启动子高甲基化和突变，有望在未来成为重要预后相关因素和药物靶点 [<xref ref-type="bibr" rid="hanspub.41757-ref42">42</xref>]。</p><p>多因素分析发现，脉管瘤栓及神经侵犯均为影响II期CRC无瘤生存及总生存的独立危险因素 [<xref ref-type="bibr" rid="hanspub.41757-ref43">43</xref>]。一项多中心回顾性研究认为：根治性切除后的IV期CRC有很高的复发可能，早期、中期和晚期复发的风险因素各不相同。早期(1年内)复发因素为直肠部位、T4、N期、脉管侵袭和肝转移，而晚期(2年或更晚)复发危险因素为肿瘤大小 &lt; 50 mm和腹膜转移 [<xref ref-type="bibr" rid="hanspub.41757-ref44">44</xref>]。钟玲的多因素Cox回归分析表明阳性淋巴结数比(LODDS)为Ⅲ结直肠癌的5年生存率的独立预后指标 [<xref ref-type="bibr" rid="hanspub.41757-ref45">45</xref>]。</p></sec><sec id="s11"><title>7. 展望</title><p>本文从CRC的病因、分型、临床表现、诊断、治疗及预后等方面综合展开综述，尤其对治疗包括早、中晚期或远处转移的方式加以归纳。但还应强调早期发现，提高患者对自身健康重视，增强医者对高危患者的筛查、早期诊断与干预对患者有重要意义。相信随着临床医师的实践、认识和总结、现代诊疗技术和水平的发展和提高，以及更多CRC相关的指南共识的提出、运用，CRC的相关治疗及预后将不断改善，将为更多CRC患者带来福音。</p></sec><sec id="s12"><title>文章引用</title><p>周海军,白铁成,刘 涛,曹 波,李恺鹏. 结直肠癌的诊断与治疗新进展New Progress in Diagnosis and Treatment of Colorectal Cancer[J]. 临床医学进展, 2021, 11(04): 1117-1124. https://doi.org/10.12677/ACM.2021.114251</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41757-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dekker, E., Tanis, P.J., Vleugels, J., et al. (2019) Colorectal Cancer. The Lancet, 394, 1467-1480.  
&lt;br&gt;https://doi.org/10.1016/S0140-6736(19)32319-0</mixed-citation></ref><ref id="hanspub.41757-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">李为民, 刘丹, 卢铀. 肺癌诊治水平的进展与提高[J]. 四川大学学报(医学版), 2014, 45(2): 289-292.</mixed-citation></ref><ref id="hanspub.41757-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">朱成章, 张维胜, 杜斌斌, 等. 肠道菌群失调与罹患结直肠癌风险的研究进展[J]. 中华结直肠疾病电子杂志, 2021, 10(1): 95-98.</mixed-citation></ref><ref id="hanspub.41757-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">卫生部医政司, 卫生部办公厅. 结直肠癌诊疗规范(2010年版) [J]. 中华外科杂志, 2011(2): 97-104.</mixed-citation></ref><ref id="hanspub.41757-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">屠世良, 叶再元, 邓高里, 等. 结直肠癌淋巴结转移的规律及其影响因素[J]. 中华胃肠外科杂志, 2007(3): 257-260.</mixed-citation></ref><ref id="hanspub.41757-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">李季, 沈艳, 姜研. CT仿真结肠镜联合肿瘤标志物检测在结直肠癌中的诊断价值[J]. 医学综述, 2021, 27(5): 1032-1036.</mixed-citation></ref><ref id="hanspub.41757-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">游金辉, 黄霓. 结直肠癌PET/CT显像的应用与研究进展[J]. 川北医学院学报, 2019, 34(1): 155-159.</mixed-citation></ref><ref id="hanspub.41757-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">豆晓锋, 邵佳栋, 李晶. PET/CT显像在结直肠癌术后复发及转移诊断中的临床应用价值[J]. 影像研究与医学应用, 2018, 2(22): 6-7.</mixed-citation></ref><ref id="hanspub.41757-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李宣海. 肿瘤标志物的检测与临床[M]. 北京: 人民卫生出版社, 1997.</mixed-citation></ref><ref id="hanspub.41757-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">崔秀玉, 李秀平, 于谨铭, 等. 血清CA199, CA242, CEA联合检测对胰腺癌的临床意义[J]. 医学检验与临床, 2010, 21(5): 14-15, 13.</mixed-citation></ref><ref id="hanspub.41757-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">孙巍, 王琼, 刘娟, 等. 血清肿瘤标志在结直肠癌诊断中的应用[J]. 中华检验医学杂志, 2000(1): 10-12.</mixed-citation></ref><ref id="hanspub.41757-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">边鹏, 刘瑞红, 张喜雨, 等. 基于病案数据的结直肠癌远处转移影响因素分析[J]. 中国病案, 2021, 22(3): 86-90.</mixed-citation></ref><ref id="hanspub.41757-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">史益凡, 林春燕, 鲍传庆, 等. 中西医结合快速康复外科理念在腹腔镜结直肠癌手术中的应用[J]. 中国中西医结合外科杂志, 2018, 24(6): 766-769.</mixed-citation></ref><ref id="hanspub.41757-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">练磊, 兰平. 国家卫健委中国结直肠癌诊疗规范解读(2020版)——外科部分[J]. 临床外科杂志, 2021, 29(1): 10-12.</mixed-citation></ref><ref id="hanspub.41757-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Andreola, S., Leo, E., Belli, F., et al. (1997) Distal Intramural Spread in Adenocarcinoma of the Lower Third of the Rectum Treated with Total Resection and Coloanal Anastomosis. Diseases of the Colon &amp; Rectum, 40, 25-29.  
&lt;br&gt;https://doi.org/10.1007/BF02055677</mixed-citation></ref><ref id="hanspub.41757-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wolmark, N. and Fisher, B. (1986) An Analysis of Survival and Treatment Failure Following Abdominoperineal and Sphincter-Saving Resection in Dukes’ B and C Rectal Carcinoma. A Report of the NSABP Clinical Trials. National Surgical Adjuvant Breast and Bowel Project. Annals of Surgery, 204, 480-489.  
&lt;br&gt;https://doi.org/10.1097/00000658-198610000-00016</mixed-citation></ref><ref id="hanspub.41757-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y., Kim, N., Min, B., et al. (2009) Factors Associated with Anastomotic Recurrence after Total Mesorectal Excision in Rectal Cancer Patients. Journal of Surgical Oncology, 99, 58-64. &lt;br&gt;https://doi.org/10.1002/jso.21166</mixed-citation></ref><ref id="hanspub.41757-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">封益飞, 唐俊伟, 王勇, 等. 肠道支架置入联合择期手术与急诊手术在梗阻性结直肠癌治疗中的对比分析[J]. 腹腔镜外科杂志, 2021, 26(3): 218-222.</mixed-citation></ref><ref id="hanspub.41757-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Borschitz, T., Wachtlin, D., Hler, M., et al. (2008) Neoadjuvant Chemoradiation and Local Excision for T2-3 Rectal Cancer. Annals of Surgical Oncology, 15, 712-720. &lt;br&gt;https://doi.org/10.1245/s10434-007-9732-x</mixed-citation></ref><ref id="hanspub.41757-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Read, T.E., Andujar, J.E., Caushaj, P.F., et al. (2004) Neoadjuvant Therapy for Rectal Cancer: Histologic Response of the Primary Tumor Predicts Nodal Status. Diseases of the Colon &amp; Rectum, 47, 825-831.  
&lt;br&gt;https://doi.org/10.1007/s10350-004-0535-x</mixed-citation></ref><ref id="hanspub.41757-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Petrelli, F., Trevisan, F., Cabiddu, M., et al. (2019) Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-Analysis of Treatment Outcomes. Annals of Surgery, 271, 1.  
&lt;br&gt;https://doi.org/10.1097/SLA.0000000000003471</mixed-citation></ref><ref id="hanspub.41757-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">肖刘牛, 朱丽, 陈颖铭, 等. II期结直肠癌术后化疗临床预后危险因素的Meta分析[J]. 循证医学, 2019, 19(3): 167-177.</mixed-citation></ref><ref id="hanspub.41757-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">樊嘉, 顾晋, 秦新裕, 等. 中国结直肠癌肝转移诊断和综合治疗指南(2020) [J]. 中国临床医学, 2021, 28(1): 129-144.</mixed-citation></ref><ref id="hanspub.41757-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Andre, T., Boni, C., Navarro, M., et al. (2009) Improved Overall Survival with Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial. Journal of Clinical Oncology, 27, 3109-3116.  
&lt;br&gt;https://doi.org/10.1200/JCO.2008.20.6771</mixed-citation></ref><ref id="hanspub.41757-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Tveit, K.M., et al. (1997) Combined Modality Treatment Including Intraoperative Radiotherapy in Locally Advanced and Recurrent Rectal Cancer. Radiotherapy and Oncology, 44, 277-282.  
&lt;br&gt;https://doi.org/10.1016/S0167-8140(97)00070-4</mixed-citation></ref><ref id="hanspub.41757-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Yu, T.K., Bhosale, P.R., Crane, C.H., et al. (2008) Patterns of Locoregional Recurrence after Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 71, 1175-1180.  
&lt;br&gt;https://doi.org/10.1016/j.ijrobp.2007.11.018</mixed-citation></ref><ref id="hanspub.41757-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Stillwell, A.P., Buettner, P.G. and Ho, Y.H. (2010) Meta-Analysis of Survival of Patients with Stage IV Colorectal Cancer Managed with Surgical Resection versus Chemotherapy Alone. World Journal of Surgery, 34, 797-807.  
&lt;br&gt;https://doi.org/10.1007/s00268-009-0366-y</mixed-citation></ref><ref id="hanspub.41757-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">van Rooijen, K.L., Shi, Q., Goey, K., et al. (2018) Prognostic Value of Primary Tumour Resection in Synchronous Metastatic Colorectal Cancer: Individual Patient Data Analysis of First-Line Randomised Trials from the ARCAD Database. European Journal of Cancer, 91, 99-106. &lt;br&gt;https://doi.org/10.1016/j.ejca.2017.12.014</mixed-citation></ref><ref id="hanspub.41757-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">王磊, 蔡建, 秦启元. 结直肠癌腹膜转移治疗的争议与思考[J]. 中华外科杂志, 2018, 56(8): 569-572.</mixed-citation></ref><ref id="hanspub.41757-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">崔书中, 王佳泓, 张相良. 肿瘤细胞减灭术联合腹腔热灌注化疗治疗结直肠癌腹膜转移癌[J]. 中国肿瘤临床, 2012, 39(22): 1691-1695.</mixed-citation></ref><ref id="hanspub.41757-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Park, E.J., Baik, S.H., Hur, H., et al. (2017) Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Cancer with Peritoneal Carcinomatosis. Medicine, 96, e6632.  
&lt;br&gt;https://doi.org/10.1097/MD.0000000000006632</mixed-citation></ref><ref id="hanspub.41757-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Portilla, A.G., Cendoya, I., Tejada, I., et al. (2005) Peritoneal Carcinomatosis of Colorectal Origin. Current Treatment. Review and Update. Revista Espanola de Enfermedades Digestivas, 97, 716.  
&lt;br&gt;https://doi.org/10.4321/S1130-01082005001000005</mixed-citation></ref><ref id="hanspub.41757-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">赵志勋, 裴炜, 熊斌, 等. 结直肠癌腹膜转移诊治中国专家意见(2017) [J]. 中华结直肠疾病电子杂志, 2017, 6(5): 360-366.</mixed-citation></ref><ref id="hanspub.41757-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Roemer-Becuwe, C., Krakowski, I. and Conroy, T. (2003) Bisphosphonates, Pain and Quality of Life in Metastatic Breast Cancer Patients: A Literature Review. Bulletin du Cancer, 90, 1097-1105.</mixed-citation></ref><ref id="hanspub.41757-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">马晨曦, 关旭, 王锡山. 结直肠癌骨转移的研究现状及治疗[J]. 中华结直肠疾病电子杂志, 2020, 9(6): 605-609.</mixed-citation></ref><ref id="hanspub.41757-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">赵亮, 苏佳灿. 结直肠癌骨转移研究进展[J]. 中国骨与关节杂志, 2012, 1(2): 182-184.</mixed-citation></ref><ref id="hanspub.41757-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Sorich, M.J., Wiese, M.D., Rowland, A., et al. (2015) Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: A Meta-Analysis of Randomized, Controlled Trials. Annals of Oncology Official Journal of the European Society for Medical Oncology, 26, 13-21.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdu378</mixed-citation></ref><ref id="hanspub.41757-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">高静, 孙志伟, 李艳艳, 等. 中国结直肠癌患者966例中KRAS和BRAF基因突变分析[J]. 中华病理学杂志, 2012(9): 579-583.</mixed-citation></ref><ref id="hanspub.41757-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">陈海霞, 何亚楠, 王维娜, 等. 结直肠癌组织中KRAS和BRAF基因突变与临床病理特征及预后的关系[J]. 现代肿瘤医学, 2021, 29(4): 626-631.</mixed-citation></ref><ref id="hanspub.41757-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">潘思琼, 陆奉科, 李山. 错配修复蛋白MLH1、MSH2、PMS2、MSH6及p53在结直肠癌中的表达及意义[J]. 海南医学, 2021, 32(1): 4-7.</mixed-citation></ref><ref id="hanspub.41757-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">黎相照, 刘焕娇, 梁敏仪, 等. 微卫星不稳定性类型及临床病理特征: 基于1394例结直肠癌患者的标本检测[J]. 南方医科大学学报, 2020, 40(11): 1645-1650.</mixed-citation></ref><ref id="hanspub.41757-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">刘荫华, 姚宏伟, 周斌, 等. 美国肿瘤联合会结直肠癌分期系统(第8版)更新解读[J]. 中国实用外科杂志, 2017(1): 6-9.</mixed-citation></ref><ref id="hanspub.41757-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">韩慧敏, 王鹏, 朱冰, 等. 脉管瘤栓在II期结直肠癌中的临床价值研究[J]. 实用肿瘤杂志, 2021, 36(1): 43-46.</mixed-citation></ref><ref id="hanspub.41757-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Kishiki, T., Lapin, B., Matsuoka, H., et al. (2018) Optimal Surveillance Protocols after Curative Resection in Patients with Stage IV Colorectal Cancer: A Multicenter Retrospective Study. Diseases of the Colon &amp; Rectum, 61, 51-57.  
&lt;br&gt;https://doi.org/10.1097/DCR.0000000000000950</mixed-citation></ref><ref id="hanspub.41757-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">钟玲, 郅程. 阳性淋巴结对数比对Ⅲ期结直肠癌预后的预测价值[J]. 消化肿瘤杂志(电子版), 2020, 12(4): 256-260.</mixed-citation></ref></ref-list></back></article>